IPCALABIPCA Laboratories Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · India Ratings: AA+ (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.3 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹2910 Cr | ₹389 Cr | 19.21% | 13.38% | ₹14.79 | 44.5x |
| Q1 FY2027 | ₹2788 Cr | ₹424 Cr | 20.04% | 15.22% | ₹15.84 | 49.2x |
| Q4 FY2026 | ₹2388 Cr | ₹307 Cr | 15.77% | 12.84% | ₹11.79 | 21.0x |
| Q3 FY2026 | ₹2393 Cr | ₹364 Cr | 17.80% | 15.20% | ₹12.86 | 26.3x |
| Q2 FY2026 | ₹2557 Cr | ₹281 Cr | 17.27% | 10.97% | ₹11.14 | 21.0x |
| Q1 FY2026 | ₹2309 Cr | ₹233 Cr | 13.70% | 10.09% | ₹9.19 | 18.9x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.